Increased striatal dopamine efflux follows scopolamine administered systemically or to the tegmental pedunculopontine nucleus.
The cholinergic cells of the tegmental pedunculopontine nucleus monosynaptically excite dopaminergic neurons of the substantia nigra. In vivo electrochemical methods were used to monitor dorsal striatal dopamine efflux in awake rats following intraperitoneal scopolamine injections and following the direct application of scopolamine to the tegmental pedunculopontine nucleus. Systemic injections of scopolamine (1.0, 3.0 or 10.0 mg/kg) resulted in dose-related increases in peak striatal dopamine oxidation currents of between 1.1 and 2.0 nA. Increases began within 10-20 min after injection and peaked after 40-90 min. Unilateral microinjections of scopolamine into the tegmental pedunculopontine nucleus (10, 50 or 100 micrograms/0.5 microliter) resulted in dose-related increases in dopamine oxidation currents that peaked 60-90 min postinjection (2.9-5.0 nA). Carbachol (4.0 micrograms/0.5 microliter) injected unilaterally into the tegmental pedunculopontine nucleus 20 min before 100 micrograms tegmental pedunculopontine nucleus scopolamine, or injected bilaterally 20 min before 3.0 mg/kg systemic scopolamine, attenuated the increases produced by scopolamine alone. The carbachol preinjection tests suggest that the effects of both systemic and tegmental pedunculopontine nucleus scopolamine treatments are mediated largely by muscarinic receptors near the tegmental pedunculopontine nucleus. These findings are consistent with the proposal that enhanced activation of substantia nigra dopamine cells results from scopolamine-induced disinhibition of the tegemental pedunculopontine nucleus cholinergic cell group via blockade of their inhibitory autoreceptors.
Chapman
C A
CA
Department of Psychology, McMaster University, Hamilton, Ontario, Canada.
Yeomans
J S
JS
Blaha
C D
CD
Blackburn
J R
JR
D000818:Animals; D002217:Carbachol / Q000494:pharmacology; D003342:Corpus Striatum / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004553:Electric Conductivity; D007274:Injections, Intraperitoneal; D008297:Male; D008845:Microinjections; D018727:Muscarinic Antagonists / Q000494:pharmacology*; D010084:Oxidation-Reduction / Q000187:drug effects; D011149:Pons / Q000502:physiology*; D051381:Rats; D011919:Rats, Inbred Strains; D012601:Scopolamine / Q000494:pharmacology*; D013681:Tegmentum Mesencephali / Q000502:physiology*
D018727:Muscarinic Antagonists; D002217:Carbachol; D012601:Scopolamine; D004298:Dopamine